Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL12 | P48061 | 2/20 | 0.74 |
| ▸ | CDC7 | O00311 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | PIM1 | P11309 | 2/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19782920 | 0.91 | CXCL12 (0.72) | CXCL12CDC7KDM4EPIM1CSNK2A2 | |
| SCHEMBL19782359 | 0.91 | CXCL12 (0.72) | CXCL12CDC7KDM4EPIM1CSNK2A2 | |
| SCHEMBL19782680 | 0.91 | CXCL12 (0.72) | CXCL12CDC7KDM4EPIM1CSNK2A2 | |
| SCHEMBL19782686 | 0.90 | CXCL12 (0.91) | CXCL12CDC7KDM4EPIM1CSNK2A2 | |
| SCHEMBL19782808 | 0.90 | CXCL12 (0.71) | CXCL12CDC7KDM4EPIM1CSNK2A2 | |
| SCHEMBL19782832 | 0.90 | CXCL12 (0.71) | CXCL12CDC7KDM4EPIM1CSNK2A2 | |
| SCHEMBL19782800 | 0.90 | CXCL12 (0.71) | CXCL12CDC7KDM4EPIM1CSNK2A2 | |
| SCHEMBL22065542 | 0.89 | CXCL12 (0.69) | CXCL12CDC7KDM4EPIM1CSNK2A2 | |
| SCHEMBL19782681 | 0.88 | CXCL12 (0.71) | CXCL12CDC7KDM4EPIM1CSNK2A2 | |
| SCHEMBL19782824 | 0.88 | CXCL12 (0.68) | CXCL12CDC7KDM4EPIM1CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2020-06-11 | — | — | US | disclosed |
| WO-2018011376-A1 | PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CCL5, CXCR3, CXCL10 | CXCL12 18/4885CDC7 2413/4885KDM4E 4286/4885 |
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CCL5, CXCR3, CXCL10 | CXCL12 18/4885CDC7 2413/4885KDM4E 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.